Sugi Predict

Sugi Predict / Compounds / SCHEMBL8009501

SCHEMBL8009501

SCHEMBL8009501

CCCOC(=O)[C@@H]1CCCN1

nearest known ligand 0.46

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ PRCP P42785 2/20 0.46
▸ TLR2 O60603 2/20 0.42
▸ PPM1B O75688 1/20 0.41
▸ PTPN1 P18031 1/20 0.41
▸ PPP1CC P36873 1/20 0.41
▸ DPP7 Q9UHL4 2/20 0.41
▸ DPP4 P27487 1/20 0.37
▸ FAP Q12884 1/20 0.37
▸ DPP8 Q6V1X1 1/20 0.37
▸ DPP9 Q86TI2 1/20 0.37
▸ NOS2 P35228 2/20 0.37
▸ NOS3 P29474 1/20 0.37
▸ NOS1 P29475 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10826223 1.00 PRCP (0.46) PRCPTLR2PPM1BPTPN1PPP1CC
Hydrochloric Acid SCHEMBL28098040 0.98 PRCP (0.45) PRCPTLR2PPM1BPTPN1PPP1CC
SCHEMBL22861527 0.95 PRCP (0.42) PRCPTLR2PPM1BPTPN1PPP1CC
SCHEMBL3666618 0.95 PRCP (0.42) PRCPTLR2PPM1BPTPN1PPP1CC
Hydrochloric Acid SCHEMBL30475358 0.93 PRCP (0.41) PRCPTLR2PPM1BPTPN1PPP1CC
SCHEMBL25885236 0.91 PPM1B (0.45) PRCPTLR2PPM1BPTPN1PPP1CC
SCHEMBL16124525 0.90 PRCP (0.42) PRCPTLR2PPM1BPTPN1PPP1CC
SCHEMBL2638667 0.90 PRCP (0.51) PRCPTLR2DPP7DPP4FAP
SCHEMBL8257937 0.90 PRCP (0.51) PRCPTLR2DPP7DPP4FAP
SCHEMBL2713588 0.90 PRCP (0.51) PRCPTLR2DPP7DPP4FAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180251486-A1 LINCOMYCIN BIOSYNTHETIC INTERMEDIATES, METHOD FOR PREPARATION, AND USE THEREOF HUZHOU CENTER OF BIO-SYNTHETIC INNOVATION, SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) 2018-09-06 — — US claimed
CN-105566411-A Lincomycin biosynthesized intermediate product and preparation method and use thereof SHANGHAI INST ORGANIC CHEMISTRY CAS 2016-05-11 — — CN claimed
US-20260015373-A1 STAT6 MODULATORS AND USES THEREOF RECLUDIX PHARMA INC (US) 2026-01-15 — — US disclosed
US-20250296912-A1 AFFINITY ILLUDOFULVENE CONJUGATES Illudent, Inc. (US) 2025-09-25 — — US disclosed
US-20250215029-A1 STAT MODULATORS AND USES THEREOF RECLUDIX PHARMA, INC. 2025-07-03 — — US disclosed
CN-120081711-A Method for preparing liquid fertilizer from lincomycin and ivermectin waste liquid 宁夏泰胜生物科技有限公司 2025-06-03 — — CN disclosed
CN-120040435-A Mangiferin and derivatives thereof, preparation method and medical application thereof 安徽中医药大学 2025-05-27 — — CN disclosed
US-12269793-B2 Affinity illudofulvene conjugates AF CHEMICALS, LLC (US) 2025-04-08 — — US disclosed
EP-4463459-A1 STAT MODULATORS AND USES THEREOF Recludix Pharma, Inc. (US) 2024-11-20 — — EP disclosed
US-20240358710-A1 METHODS, COMPOSITIONS AND DEVICES FOR TREATING CANCER WITH ILLUDOFULVENES AF CHEMICALS, LLC (US) 2024-10-31 — — US disclosed
CN-118804917-A STAT modulators and uses thereof 瑞克鲁迪克斯制药股份有限公司 2024-10-18 — — CN disclosed
EP-3155436-A1 ISOBARIC MASS LABELS Electrophoretics Limited (GB) 2017-04-19 — — EP disclosed
CN-105566411-A Lincomycin biosynthesized intermediate product and preparation method and use thereof SHANGHAI INST ORGANIC CHEMISTRY CAS 2016-05-11 — — CN disclosed
WO-2015189413-A1 ISOBARIC MASS LABELS ELECTROPHORETICS LIMITED (GB) 2015-12-17 — — WO disclosed
CN-104159584-A Aprepitant L-proline solvate-compositions and co-crystals NUFORMIX LTD 2014-11-19 — — CN disclosed
WO-2013076659-A1 APREPITANT L-PROLINE SOLVATES - COMPOSITIONS AND COCRYSTALS NUFORMIX LIMITED (GB) 2013-05-30 — — WO disclosed
US-8232403-B2 Bicyclic derivatives as CETP inhibitors NOVARTIS AG (CH) 2012-07-31 — — US disclosed
US-20090227580-A1 Bicyclic derivatives as CETP inhibitors NOVARTIS AG (CH) 2009-09-10 — — US disclosed
US-6136580-A POLYPEPTIDE WITH ENZYMATIC ACTIVITY; FOR DIAGNOSIS, PREVENTION AND TREATMENT OF INFLAMMATION, TUMOR METASTASIS AND TISSUE REJECTION; ANTITUMOR AGENTS THE BURNHAM INSTITUTE (US) 2000-10-24 — — US disclosed
CN-1021044-C PREPARATION METHOD FOR ACIDOPHOBIC-METHYL PROPYL PROLINE INTERMEDIATE D-3-ACETYLSULFURIC-2-METHYL-PROPIONY-L-PROLINE SHANGHAI MEDICAL INDUSTRY INST (CN) 1993-06-02 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250296912-A1 AFFINITY ILLUDOFULVENE CONJUGATES OGFR, TNFSF11, FCER2 PRCP 255/4885TLR2 1368/4885PPM1B 4595/4885
US-20260015373-A1 STAT6 MODULATORS AND USES THEREOF STAT6, STAT5A, STAT3 PRCP 2863/4885TLR2 658/4885PPM1B 1106/4885
US-20250215029-A1 STAT MODULATORS AND USES THEREOF STAT6, STAT3, STAT5A PRCP 2781/4885TLR2 883/4885PPM1B 293/4885
US-20180251486-A1 LINCOMYCIN BIOSYNTHETIC INTERMEDIATES, METHOD FOR PREPARATION, AND USE THEREOF COASY, DHPS, DCXR PRCP 891/4885TLR2 1205/4885PPM1B 2880/4885
US-20240358710-A1 METHODS, COMPOSITIONS AND DEVICES FOR TREATING CANCER WITH ILLUDOFULVENES MYC, MYCBP, TP53 PRCP 3474/4885TLR2 483/4885PPM1B 1694/4885
US-20090227580-A1 Bicyclic derivatives as CETP inhibitors CETP, LCAT, CES1 PRCP 80/4885TLR2 3334/4885PPM1B 4315/4885
US-12269793-B2 Affinity illudofulvene conjugates OGFR, TNFSF11, FCER2 PRCP 255/4885TLR2 1368/4885PPM1B 4595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.